Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Esprit Pharma acquires Sanctura XR marketing rights

Aug. 16, 2007

Positive preclinical results from Quark's RNAi compound in acute renal failure

Aug. 9, 2007

Lilly receives approval in Japan for Cialis for erectile dysfunction

Aug. 8, 2007

FDA approves Indevus's Sanctura XR for once-daily treatment of OAB

Aug. 7, 2007

Recent patent claims series of compounds for the treatment of urinary incontincence

Aug. 2, 2007

Recent Astellas patent discloses novel treatment option for urological disorders

July 20, 2007

Plethora secures funds for development of Invicorp for treatment of ED

July 18, 2007

Topline findings from North American Zuidex study

July 16, 2007

Biogen Idec and Cardiokine to codevelop lixivaptan for hyponatremia

July 6, 2007

New agents for renal and urological disorders reported by Toray

July 4, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...